Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma

Inclusion Criteria:

1. Patients with a physician-diagnosed history of moderate to severe asthma for a period
of at least one year prior to screening.

2. Patients on a stable therapy regimen of asthma for at least 3 months prior to
screening with at least medium dose inhaled glucocorticoid and at least one additional
asthma controller medication (such as inhaled long-acting bronchodilator, leukotriene
antagonist, theophylline, stable low dose glucocorticoid, etc).

3. Acceptable and reproducible spirometry with FEV1 ≥ 40 and ≤ 90% of predicted at
screening and baseline (re-testing is allowed once).

4. ACQ score ≥ 1.5 at screening and baseline (re-testing is allowed once).

5. Total serum IgE < 150 IU/mL

6. Peripheral blood eosinophils <300/μL

Exclusion Criteria:

1. Previous use of biologics or other concomitant medications within the time periods
specified in the SOM/protocol.

2. History of ongoing, chronic, or recurrent moderate or severe infectious disease.

3. Patients who have smoked or inhaled nicotine or tobacco products within the 6 month
period prior to Visit 1 or who have a smoking history of greater than 10 pack years.

4. Patients who have had an asthma attack/exacerbation requiring systemic corticosteroids
for at least 3 continuous days within 4 weeks prior to screening.

5. Patients who have had a respiratory tract infection or asthma worsening within 4 weeks
prior to Visit 1 or during the screening period.

6. Women of child-bearing potential unless they are using highly effective methods of
contraception during dosing and for 13 weeks after stopping of investigational drug.